Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6976 to 6990 of 7675 results

  1. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development [GID-TA10489] Expected publication date: TBC

  2. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued [GID-TA10495]

  3. Workplace health - older employees

    Discontinued [GID-PHG59]

  4. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

  5. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

  6. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued [GID-TAG369]

  7. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued [GID-TAG439]

  8. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

  9. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued [GID-TA10177]

  10. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued [GID-TA10271]

  11. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued [GID-TAG404]

  12. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued [GID-TAG412]

  13. Avelumab for previously treated platinum-resistant ovarian cancer ID1497

    In development [GID-TA10404] Expected publication date: TBC

  14. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued [GID-TAG414]